These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27535334)

  • 1. Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.
    Fu Y; Jovelet C; Filleron T; Pedrero M; Motté N; Boursin Y; Luo Y; Massard C; Campone M; Levy C; Diéras V; Bachelot T; Garrabey J; Soria JC; Lacroix L; André F; Lefebvre C
    Cancer Res; 2016 Oct; 76(20):5954-5961. PubMed ID: 27535334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dynamic range of circulating tumor DNA in metastatic breast cancer.
    Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
    Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
    Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH
    Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
    Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
    Rothé F; Laes JF; Lambrechts D; Smeets D; Vincent D; Maetens M; Fumagalli D; Michiels S; Drisis S; Moerman C; Detiffe JP; Larsimont D; Awada A; Piccart M; Sotiriou C; Ignatiadis M
    Ann Oncol; 2014 Oct; 25(10):1959-1965. PubMed ID: 25185240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
    Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
    De Mattos-Arruda L; Weigelt B; Cortes J; Won HH; Ng CKY; Nuciforo P; Bidard FC; Aura C; Saura C; Peg V; Piscuoglio S; Oliveira M; Smolders Y; Patel P; Norton L; Tabernero J; Berger MF; Seoane J; Reis-Filho JS
    Ann Oncol; 2014 Sep; 25(9):1729-1735. PubMed ID: 25009010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
    Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
    Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.
    Butler TM; Johnson-Camacho K; Peto M; Wang NJ; Macey TA; Korkola JE; Koppie TM; Corless CL; Gray JW; Spellman PT
    PLoS One; 2015; 10(8):e0136407. PubMed ID: 26317216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole exome sequencing of rare aggressive breast cancer histologies.
    Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
    Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
    Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
    Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of FNA samples for whole-exome sequencing and detection of somatic mutations in breast cancer surgical specimens.
    Lee HB; Joung JG; Kim J; Lee KM; Ryu HS; Lee HO; Moon HG; Park WY; Noh DY; Han W
    Cancer Cytopathol; 2015 Nov; 123(11):669-77. PubMed ID: 26265110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma.
    Luo H; Li H; Hu Z; Wu H; Liu C; Li Y; Zhang X; Lin P; Hou Q; Ding G; Wang Y; Li S; Wei D; Qiu F; Li Y; Wu S
    Biochem Biophys Res Commun; 2016 Mar; 471(4):596-602. PubMed ID: 26876573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.
    Beránek M; Sirák I; Vošmik M; Petera J; Drastíková M; Palička V
    Acta Medica (Hradec Kralove); 2016; 59(2):54-8. PubMed ID: 27526306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.
    Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
    Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
    Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
    Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.